Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1

Status

Active not recruiting 23Recruiting 16Completed 12Unknown 4Terminated 4Not yet recruiting 4Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 4Neoplasms 2Lymphoma 2Leukemia, Myeloid, Acute 2Leukemia 2Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Lymphoma, Large B-Cell, Diffuse 1Hematologic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Dexamethasone 112Bortezomib 61Lenalidomide 49Cyclophosphamide 49Calcium Dobesilate 43pomalidomide 32Melphalan 31fludarabine 25Filgrastim 25carfilzomib 22fludarabine phosphate 21daratumumab 20Granulocyte Colony-Stimulating Factor 16Whole-Body Irradiation 15Antilymphocyte Serum 15dexamethasone acetate 14Mycophenolic Acid 14Thalidomide 13Tacrolimus 13Cyclosporine 13Busulfan 13Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Radiotherapy 9Etoposide 9belantamab mafodotin 8Rituximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Multiple Myeloma × isatuximab × Clear all
NCT05675319 2026-01-05

AlloRelapseMM

Universitätsklinikum Hamburg-Eppendorf

Phase 3 Terminated
28 enrolled
Plasma cell

Multiple Myeloma

NCT03530683 2024-09-03

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Pfizer

Phase 1 Terminated
189 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Plasma Cell

NCT04083898 2024-03-19

Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

Washington University School of Medicine

Phase 1 Terminated
15 enrolled
Plasma cell

Multiple Myeloma

NCT04912427 2024-02-09

Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease

Washington University School of Medicine

Phase 1 Terminated
1 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡